Auris Medical Reports Third Quarter 2018 Financial Results and Provides Business Update
(WorldNews Switzerland)

Positive outcomes from second Phase 1 trial with intranasal betahistine Further evidence for betahistine`s preventive effects in antipsychotic-induced weight gain Progressing intranasal betahistine program towards proof-of-concept studies Partnering process initiated for AM-111 program Sonsuvi® accepted as brand name for AM-111 Zug, Switzerland, November 15, 2018 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, today announced financial results for the third quarter ended September 30, 2018 and provided a business update. `We have continued to make great progress with our...